OTC labeling exemption
This article was originally published in The Tan Sheet
Executive Summary
Zee Medical should implement asterisk notations for over-inclusive inactive ingredient listing for company's PainAid Pain Relief Tablets, FDA tells firm in Dec. 10 letter. In November 1999, Zee was granted FDA permission to use phrase "may contain" to list inactive ingredients. However, in November 2001 responses to citizen petitions filed by an Atlanta law firm and CHPA, agency said manufacturers should, instead, use phrase "contains one or more of these ingredients" and place asterisks next to inactives that may or may not appear in the product (1"The Tan Sheet" Nov. 12, 2001, p. 4)...
You may also be interested in...
OTC Inactive Ingredient Labeling Guidance To Be Issued By FDA
FDA plans to issue a guidance to industry on how to list inactive ingredients that may or may not be present in OTC drug labeling
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.